市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Biomea Fusion, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
1.9
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.88 |
|
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 25.02% |
| 机构持股比例 | 63.55% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 40.00 (HC Wainwright & Co., 1,795.74%) | 购买 |
| 中 | 28.00 (1,227.01%) | |
| 低 | 16.00 (D. Boral Capital, 658.29%) | 购买 |
| 平均值 | 28.00 (1,227.01%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 2.45 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Apr 2025 | 40.00 (1,795.73%) | 购买 | 2.11 |
| 31 Mar 2025 | 40.00 (1,795.73%) | 购买 | 2.13 | |
| D. Boral Capital | 24 Mar 2025 | 16.00 (658.29%) | 购买 | 2.79 |
| 19 Mar 2025 | 16.00 (658.29%) | 购买 | 2.73 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合